AnaptysBio Stock Rises After Hours on Upbeat Q2, Fiscal 2026 Results

AnaptysBio Inc. stock gained 3.8% in after-hours trading after the company posted upbeat second-quarter and transitional fiscal 2026 financial results late in the regular session.

Anaptys reported $27.5 million in revenue, topping analyst expectations of roughly $20 million by more than 36%. The San Diego-based company, which focuses on managing financial collaborations for Jemperli with Tesaro (a GSK company) and Quimilza (imsidolimab) with Vanda, released results for the quarter ended June 30, 2026.

CEO Daniel Faga adopted a notably optimistic tone in the earnings release, citing a pipeline of near-term value catalysts. He highlighted additional ex-U.S. Jemperli sales acceleration, an expected FDA approval of Jemperli as monotherapy for dMMR/MSI-H neoadjuvant rectal cancer, a litigation judgment anticipated with GSK and Tesaro, and a projected FDA approval of Quimilza in GPP in December 2026.

The broader market offered a constructive backdrop, as Wall Street surged Monday on strength in technology shares.

AI support was used to generate this article, which was reviewed by an editor. See our T&C for more information.